The pharma industry in India is entering a very interesting variant of the post-digital marketing era. The term “post-digital marketing” is used to depict a state where the lines between physical and digital blur considerably for a customer. However, in the context of pharma, this means a state where the industry has stopped questioning the need for digital and has begun to implement very interesting digital marketing initiatives.

Glosing the Gender Gap

Guest Editorial by Sharadha Iyer on the urgent need to close the gender gap in the Indian Pharma Industry

The ‘Amazonization’ of Healthcare

Inside this Issue 1. The 'Amazonization' of Healthcare by Salil Kallianpur Amazon's drive...

IMS Health Market Reflection Report for September 2016

The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,278 crs in the month of September 2016 clocking a strong 10% growth over same period last year (SPLY). On a MAT September basis, the industry was valued at Rs. 111,022 crores and reflected a 13% growth with volumes contributing around 40% of this growth and New Introductions playing an important role with around 38% contribution to the overall growth.

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market....

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...

Rajesh Bhogavalli has been appointed as Chief Commercial Officer of ACG Group.

With over 25 years of leadership experience across commercial...

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Mounjaro is the Exceptional Growth Story: Ranks #1

The July Brand Monitor by Pharmarack shows a healthy...

Marketing

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market....

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...

Rajesh Bhogavalli has been appointed as Chief Commercial Officer of ACG Group.

With over 25 years of leadership experience across commercial...

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Mounjaro is the Exceptional Growth Story: Ranks #1

The July Brand Monitor by Pharmarack shows a healthy...

Policies/Sales

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market....

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...

Rajesh Bhogavalli has been appointed as Chief Commercial Officer of ACG Group.

With over 25 years of leadership experience across commercial...

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Mounjaro is the Exceptional Growth Story: Ranks #1

The July Brand Monitor by Pharmarack shows a healthy...

Strategy

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market....

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...

Rajesh Bhogavalli has been appointed as Chief Commercial Officer of ACG Group.

With over 25 years of leadership experience across commercial...

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Mounjaro is the Exceptional Growth Story: Ranks #1

The July Brand Monitor by Pharmarack shows a healthy...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Genome Valley: A Signal of Transformation in Indian Pharma?

India’s pharmaceutical sector is at a tipping point. Long...

Cipla–Pfizer Deal: How “Ordinary” Brands Are Fueling an Extraordinary Power Shift in Indian Pharma

What’s really happening in the Cipla–Pfizer tie‑up At first glance,...

Indian Pharmaceutical Innovation – Post TRIPS

It is the twentieth anniversary of the new patent act in January 2025. The post-patent (P20) era is a story of resilience, determination, and charting a course that set global ambitions, a story of finding opportunity in adversity. It is a story for case studies in business schools, in international studies, in global health efforts.